METHODS	Immunohistochemical expression of tumor-specific VEGF-A , VEGFR2 , and HER2 was evaluated in tumor specimens from premenopausal breast cancer patients randomly assigned to 2 years of tamoxifen or no treatment ( n = 564 ) , with 14 years of follow-up .\